Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Outset Medical, Inc. (NASDAQ: OM) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. Outset is a medical technology manufacturer focused on the Tablo Hemodialysis System, and its filings offer detail on financial performance, risk factors, and the business model behind its dialysis platform.
Among the key documents, investors can review Form 10-K annual reports and Form 10-Q quarterly reports, which typically include discussions of product revenue from Tablo consoles, recurring revenue from Tablo consumables and services, gross margin trends, operating expenses, and liquidity. These filings also reference the risks and uncertainties that could affect Outset’s results and the regulatory environment in which it operates.
Outset’s Form 8-K current reports are particularly relevant for tracking material events. For example, the company has filed 8-Ks to furnish press releases announcing second and third quarter financial results and updated or revised revenue guidance. Such filings summarize the nature of the event and incorporate the related press release by reference.
On this page, users can also monitor insider transaction reports on Form 4, proxy statements on Schedule 14A when available, and other submissions that shed light on governance, executive compensation, and ownership changes.
Stock Titan enhances these filings with AI-powered summaries that explain the main points of lengthy documents, highlight notable changes from prior periods, and surface items such as revenue mix, margin commentary, and forward-looking statements. Real-time updates from EDGAR help ensure that new OM filings, including 10-Ks, 10-Qs, 8-Ks, and Form 4 insider reports, are quickly reflected and summarized for easier review.
Outset Medical, Inc. insider filing shows tax-related share sales by Chair and CEO Leslie Trigg. On January 20, 2026, Trigg sold 11,794 shares of common stock at $5.12 per share, followed by a sale of 2,120 shares at $5.05 per share on January 21, 2026.
According to the footnote, these transactions were the required number of shares sold to cover partial tax withholding obligations tied to the vesting of 32,552 RSU-based shares granted on June 10, 2025, executed as a "sell to cover" and not as discretionary trades. After these sales, Trigg directly beneficially owned 105,703 shares of common stock and indirectly held additional shares through trusts.
Outset Medical insider plans additional stock sale under Rule 144. The filing indicates that Leslie Trigg intends to sell 2,120 shares of Outset Medical common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 10,696.59. The shares relate to equity compensation and are part of a broader pattern of recent sales.
The notice also reports prior sales over the past three months, including 916 shares on 11/17/2025, 1,795 shares on 01/07/2026, and 11,794 shares on 01/20/2026, for gross proceeds of 4,213.60, 7,664.65, and 60,385.28, respectively. The issuer had 18,153,090 shares of common stock outstanding, providing context for the scale of these transactions.
Omnicell stockholder Marc Nash filed a notice of proposed sale under Rule 144. He plans to sell 980 shares of common stock through Morgan Stanley Smith Barney LLC on or about 01/21/2026, with an aggregate market value of $4,876.11. The shares are listed on NASDAQ, and the issuer had 18,153,090 shares outstanding at the time stated.
The securities to be sold were acquired on 01/17/2026 via settlement of 14,839 vested restricted stock units as equity compensation for services rendered. Over the prior three months, Nash sold additional common shares, including 247 shares for $1,136.20, 108 shares for $461.16, and 5,375 shares for $27,520.00. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about the issuer.
OM insider John Brottem has filed a Form 144 indicating an intention to sell 1,180 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ around 01/21/2026. The aggregate market value of these shares is listed as $5,913.82, compared with 18,153,090 shares of common stock outstanding. The shares to be sold stem from equity compensation: on 01/17/2026, Brottem acquired 17,997 shares via settlement of vested restricted stock units as payment for services.
Over the prior three months, Brottem has sold additional OM common stock, including 388 shares for $1,784.80 on 11/17/2025, 244 shares for $956.48 on 01/07/2026, and 9,314 shares for $47,682.76 on 01/20/2026. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
A holder of common stock in OM has filed a notice of proposed sale under Rule 144. The filer plans to sell 5,375 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 27,520.00, on or about 01/20/2026 on the NASDAQ market. The seller reports that 18,153,090 shares of this class of common stock are outstanding.
The securities to be sold were acquired on 01/17/2026 via settlement of vested restricted stock units granted by the issuer as equity compensation for services rendered, totaling 14,839 shares. Over the prior three months, the same person sold smaller amounts of common stock, including 247 shares on 11/17/2025 for gross proceeds of 1,136.20 and 108 shares on 01/07/2026 for gross proceeds of 461.16.
Outset Medical insider plans Rule 144 stock sale. A holder of Outset Medical (symbol OM) common stock, identified as Leslie Trigg, filed notice to sell 11,794 shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 60,385.28. The filing states that 18,153,090 shares of common stock were outstanding. The shares to be sold come from 32,552 shares of common stock acquired on 01/17/2026 through settlement of vested restricted stock units as equity compensation for services rendered. In the past three months, the same seller reported two sales totaling 2,711 shares of common stock, generating combined gross proceeds of 11,878.25.
OM received a notice that insider John Brottem plans to sell 9,314 shares of its common stock through Morgan Stanley Smith Barney LLC on or about 01/20/2026 on the NASDAQ market. The filing lists an aggregate market value of $47,682.76 for these shares, compared with 18,153,090 shares of common stock outstanding.
The securities to be sold were acquired on 01/17/2026 through settlement of 17,997 vested restricted stock units as equity compensation for services rendered. The notice also reports that during the prior three months, Brottem sold 388 shares on 11/17/2025 for $1,784.80 and 244 shares on 01/07/2026 for $956.48. By signing, the seller represents they are not aware of undisclosed material adverse information about OM.
BML Investment Partners, L.P., a Delaware limited partnership, reported a significant ownership position in Outset Medical, Inc. common stock on a Schedule 13G. BML disclosed beneficial ownership of 1,705,876 shares of common stock, representing 9.4% of the outstanding class.
BML reported shared voting and dispositive power over all 1,705,876 shares, with no sole voting or dispositive authority. The filing is signed by Braden M. Leonard on behalf of BML Capital Management, LLC, the general partner of BML Investment Partners, L.P., and notes that Leonard is deemed an indirect owner of these shares. The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Outset Medical, indicating a passive investment intent.
Outset Medical, Inc. director Karen Prange reported an equity grant in the form of restricted stock units. On January 9, 2026, she was awarded 18,667 RSUs, each representing a contingent right to receive one share of Outset Medical common stock at a price of $0.00 per unit.
The RSUs vest quarterly over three years, conditioned on her continued service with the company through each applicable vesting date. Following this grant, she beneficially owns 18,667 shares of common stock directly.
Outset Medical, Inc. director reports no beneficial ownership. Karen Prange, identified as a director of Outset Medical, Inc. (symbol OM), filed an initial statement of beneficial ownership of securities as of 01/09/2026. The filing states that no securities are beneficially owned, and both the non-derivative and derivative securities tables contain no holdings. The form is filed by a single reporting person and includes a power of attorney authorizing execution of the filing on her behalf.